Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography

To assess the hepatic disposition of erlotinib, we performed positron emission tomography (PET) scans with [(11)C]erlotinib in healthy volunteers without and with oral pretreatment with a therapeutic erlotinib dose (300 mg). Erlotinib pretreatment significantly decreased the liver exposure to [(11)C...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Martin, Matsuda, Akihiro, Wulkersdorfer, Beatrix, Philippe, Cécile, Traxl, Alexander, Özvegy‐Laczka, Csilla, Stanek, Johann, Nics, Lukas, Klebermass, Eva‐Maria, Poschner, Stefan, Jäger, Walter, Patik, Izabel, Bakos, Éva, Szakács, Gergely, Wadsak, Wolfgang, Hacker, Marcus, Zeitlinger, Markus, Langer, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083370/
https://www.ncbi.nlm.nih.gov/pubmed/28940241
http://dx.doi.org/10.1002/cpt.888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083370/
https://www.ncbi.nlm.nih.gov/pubmed/28940241
http://dx.doi.org/10.1002/cpt.888

Ejemplares similares